SCHEMBL664026

SCHEMBL664026

CCc1c(O)ccc(Cl)c1C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.39
MAPK1 P28482 1/20 0.39
ESR1 P03372 4/20 0.39
ESR2 Q92731 4/20 0.39
HSD17B10 Q99714 3/20 0.36
ALDH1A1 P00352 2/20 0.36
KDM4E B2RXH2 1/20 0.36
GLA P06280 1/20 0.36
GAA P10253 1/20 0.36
HPGD P15428 1/20 0.36
CASP1 P29466 1/20 0.36
CASP7 P55210 1/20 0.36
TRPA1 O75762 1/20 0.35
TP53 P04637 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
HIF1A Q16665 1/20 0.35
TSHR P16473 2/20 0.33
TDP1 Q9NUW8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Benzene SCHEMBL573759 0.96 ESR2 (0.37) CYP3A4MAPK1ESR1ESR2HSD17B10
SCHEMBL875815 0.83 CNR1 (0.38) CYP3A4MAPK1ESR1ESR2HPGD
SCHEMBL4407869 0.83 CYP3A4 (0.39) CYP3A4MAPK1ESR1ESR2HSD17B10
SCHEMBL2166705 0.82 MAPK1 (0.46) CYP3A4MAPK1ESR1ESR2KDM4E
SCHEMBL648577 0.81 ESR1 (0.47) ESR1ESR2HSD17B10ALDH1A1KDM4E
SCHEMBL11891680 0.81 ALDH1A1 (0.36) ALDH1A1TP53CYP2C9CYP2C19SMN1; SMN2
SCHEMBL23227095 0.80 CYP3A4 (0.52) CYP3A4MAPK1ESR1ESR2HSD17B10
SCHEMBL2168406 0.79 TYR (0.53) CYP3A4ESR1HSD17B10ALDH1A1KDM4E
SCHEMBL17232508 0.77 NOS3 (0.38) CYP3A4ALDH1A1
SCHEMBL983528 0.77 ESR1 (0.41) ESR1ESR2HSD17B10ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230203063-A1 TRICYCLIC PYRIDONES AND PYRIMIDONES ERASCA, INC. 2023-06-29 US disclosed
CN-107743421-B Apparatus and method for applying a composition to a surface 宝洁公司 2021-02-09 CN disclosed
CN-112118831-A Tabletted chewing gum suitable for active pharmaceutical ingredients 费尔廷制药公司 2020-12-22 CN disclosed
CN-110650721-A Coated particles and uses thereof 强生消费者公司 2020-01-03 CN disclosed
CN-109414432-A Antimicrobial compounds and methods of use thereof 港大科桥有限公司 2019-03-01 CN disclosed
US-20120046293-A1 RENIN INHIBITORS MERCK FROSST CANADA LTD. (CA) 2012-02-23 US disclosed
US-8063105-B2 Renin inhibitors MERCK CANADA INC. (CA) 2011-11-22 US disclosed
US-20090281103-A1 Renin Inhibitors MERCK CANADA INC. (CA) 2009-11-12 US disclosed
EP-1910272-A1 RENIN INHIBITORS Merck Frosst Canada Ltd. (CA) 2008-04-16 EP disclosed
WO-2007009250-A1 RENIN INHIBITORS MERCK FROSST CANADA LTD. (CA) 2007-01-25 WO disclosed
WO-1994026245-A1 ORAL CARE COMPOSITIONS CONTAINING ZINC OXIDE PARTICLES CHURCH & DWIGHT CO., INC. (US) 1994-11-24 WO disclosed
WO-1994026244-A1 ORAL CARE COMPOSITIONS CONTAINING ZINC OXIDE PARTICLES AND SODIUM BICARBONATE CHURCH & DWIGHT CO., INC. (US) 1994-11-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120046293-A1 RENIN INHIBITORS REN, ACE, AGTR1 CYP3A4 774/4885MAPK1 830/4885ESR1 3018/4885
US-20230203063-A1 TRICYCLIC PYRIDONES AND PYRIMIDONES TYMS, TYMP, DHFR CYP3A4 45/4885MAPK1 2326/4885ESR1 3242/4885
US-20090281103-A1 Renin Inhibitors REN, ACE, AGT CYP3A4 531/4885MAPK1 497/4885ESR1 4199/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.